Sequence information
DRAVP ID DRAVPc014
Name Peginterferon alfa-2a
Sequence
Molecular Formula Not Available
Condition/Disease Chronic HCV infection, Chronic HBV infection
Group Approved
Type Protein
Description Peginterferon alfa-2a is a form of recombinant interferon used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). Peginterferon alfa-2a is available as a fixed dose injector (tradename Pegasys) used for the treatment of chronic Hepatitis C. Approved in 2002 by the FDA, Pegasys is indicated for the treatment of HCV with Ribavirin or other antiviral drugs
Active sequence/Structure
External Links
DrugBank Accession Number DB00008
Pubchem ID 46504860
CHEMBL ID CHEMBL1201560
UNII Q46947FE7K
CAS 198153-51-4
ClinicalTrails Information
| NCT Number | Study Title | Condition/Disease | Status | Phase | Sponsor |
|---|---|---|---|---|---|
| NCT00910975 | Individualized Duration of Peg-interferon/Ribavirin Treatment of Hepatitis C (TTG1) | Chronic Hepatitis C Genotype 1 Treatment | Completed | Phase 4 | Göteborg University |
| NCT03084250 | The Investigation of Peginterferon Alfa-2a on Optimal in Chronic Hepatitis B Patients Who Have a High Risk of HCC | Viral Hepatitis B Treatment | Active, not recruiting | Phase 4 | Shanghai Nanhui Nanhua Hospital |
| NCT00356486 | Viral Kinetics of Treatment With Peginterferon Alpha-2a, Ribavirin and Epoetin β in Patients Coinfected HCV/HIV | Human Immunodeficiency Virus (HIV) Infections | Completed | Phase 4 | Germans Trias i Pujol Hospital |
| NCT00845676 | Treatment of Acute Hepatitis C Virus in HIV Co-Infection | Human Immunodeficiency Virus (HIV) Infections / Hepatitis C Virus (HCV) Infection | Completed | Phase 4 | University of California, San Francisco |
| NCT01686789 | Randomized Controlled Open Label Trial of Peg Alpha 2a Interferon and Adjusted-dose of Ribavirin vs. Standard Therapy in the Treatment of Naive Chronic Hepatitis C Patients Infected With Genotype 4 | Chronic Hepatitis C Virus (HCV) Infection | Completed | Phase 4 | King Abdulaziz Medical City |
| NCT00077649 | A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Combination With COPEGUS (Ribavirin) in Interferon-Naive Patients With Chronic Hepatitis C Infection (CHC). | Chronic Hepatitis C Virus (HCV) Infection | Completed | Phase 4 | Hoffmann-La Roche |
| NCT00680173 | Peripheral Blood Mononuclear Cell (PBMC) Gene Expression in HCV Genotype 1 Patients (PBMC) | Chronic Hepatitis C Virus (HCV) Infection | Completed | Phase 4 | Kaohsiung Medical University Chung-Ho Memorial Hospital |
